Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Diabetes mellitus is a metabolic disease that is characterized by persistent elevations in blood glucose (hyperglycemia). This persistent elevated blood glucose causes damage to blood vessels on a microvascular (retinopathy, nephropathy, and neuropathy) and macrovascular (peripheral artery disease, cardiovascular disease) level. Diabetes is one of the most common chronic diseases in Canada. Diabetes Canada estimated there were 3.4 million people (9.3% of the population) with diabetes in 2015 and, by 2025, this number will increase to five million people (12.1%).
The objective was to perform a systematic review of the beneficial and harmful effects of ertugliflozin 5 mg and 15 mg tablets in combination with metformin, or metformin and sitagliptin, to improve glycemic control in adult patients with type 2 diabetes mellitus when these therapies, along with diet and exercise, do not provide adequate glycemic control.
This review was conducted in tandem with the evaluation of ertugliflozin 5 mg and 15 mg tablets (Steglatro), which includes additional study data and an appraisal of the manufacturer-submitted indirect treatment comparison that are not included in this report.
Contents
Version: Final (with redactions)
- NLM CatalogRelated NLM Catalog Entries
- Review Clinical Review Report: Ertugliflozin (Steglatro): (Merck Canada Inc.): Indication: Type 2 Diabetes Mellitus[ 2019]Review Clinical Review Report: Ertugliflozin (Steglatro): (Merck Canada Inc.): Indication: Type 2 Diabetes Mellitus. 2019 Feb
- Review Alogliptin (Nesina) for Type 2 Diabetes Mellitus[ 2015]Review Alogliptin (Nesina) for Type 2 Diabetes Mellitus. 2015 Aug
- Review Pharmacoeconomic Review Report: Ertugliflozin (Steglatro): (Merck Canada Inc.): Indication: Type 2 Diabetes Mellitus[ 2019]Review Pharmacoeconomic Review Report: Ertugliflozin (Steglatro): (Merck Canada Inc.): Indication: Type 2 Diabetes Mellitus. 2019 Feb
- Review Alogliptin Plus Metformin (Kazano) for Type 2 Diabetes Mellitus[ 2015]Review Alogliptin Plus Metformin (Kazano) for Type 2 Diabetes Mellitus. 2015 Aug
- Review FreeStyle Libre Flash Glucose Self-Monitoring System: A Single-Technology Assessment[ 2017]Review FreeStyle Libre Flash Glucose Self-Monitoring System: A Single-Technology AssessmentBidonde J, Fagerlund BC, Frønsdal KB, Lund UH, Robberstad B. 2017 Aug 21
- Common Drug Review New Combination Product: Ertugliflozin/Metformin Fixed-Dose C...Common Drug Review New Combination Product: Ertugliflozin/Metformin Fixed-Dose Combination (Segluromet)
Your browsing activity is empty.
Activity recording is turned off.
See more...